Serotonergic 5-HT2B receptors in mitral valvulopathy: bone marrow mobilization of endothelial progenitors.

Date publication

août 2017

Journal

British journal of pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GACHET Christian

Tous les auteurs :
Ayme-Dietrich E, Lawson R, Côté F, de Tapia C, Da Silva S, Ebel C, Hechler B, Gachet C, Guyonnet J, Rouillard H, Stoltz J, Quentin E, Banas S, Daubeuf F, Frossard N, Gasser B, Mazzucotelli JP, Hermine O, Maroteaux L, Monassier L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28806488

Résumé

Valvular heart disease is highly prevalent in industrialized countries. Chronic use of anorexigens, amphetamine or ergot derivatives targeting the serotonin system has been associated with valvular heart disease.

Mots clés

Animals, Bone Marrow Transplantation, Endothelial Progenitor Cells, metabolism, Heart Valve Diseases, metabolism, Male, Mice, Transgenic, Mitral Valve, drug effects, Norfenfluramine, pharmacology, Receptor, Serotonin, 5-HT2A, genetics, Receptor, Serotonin, 5-HT2B, genetics, Serotonin 5-HT2 Receptor Antagonists, pharmacology

Référence

Br. J. Pharmacol.. 2017 Aug;: